Equities

Bajaj Healthcare Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert
BAJAJHCARE:NSI

Bajaj Healthcare Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (INR)354.25
  • Today's Change-1.25 / -0.35%
  • Shares traded7.06k
  • 1 Year change-40.36%
  • Beta1.1675
Data delayed at least 15 minutes, as of Feb 16 2026 03:59 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bajaj Healthcare Limited is an India-based pharmaceutical company. The Company is engaged in activities of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), bulk drugs, branded and generic formulations. It is focused on development, manufacturing and supply of amino acids, nutritional supplements and API for pharmaceutical, nutraceuticals and food industries. It operates through three segments: APIs, Finished Dosage Formulations (FDFs), and Intermediates. Its APIs include Ascorbic Acid IP, Sodium Ascorbate, Ferrous Ascorbate, and others. Its Intermediary products include Calcium Phosphoryl Choline Chloride (CPCC) and Chlorhexidine (CH Base). It offers a range of FDFs forms, including tablets, caplets, capsules, and oral powders, all available in bulk quantities. The FDFs products include Cholecalciferol Sachet, Ticagrelor Tablet, Pancreatin Capsules, levofloxacin Tablets IP, Bisacodyl Tablet IP, and others.

  • Revenue in INR (TTM)6.12bn
  • Net income in INR523.16m
  • Incorporated1993
  • Employees904.00
  • Location
    Bajaj Healthcare Ltd202-204Faiz-E-Qutbi, 375,Narshi Natha StreetTHANE 400604IndiaIND
  • Phone+91 2 240177400
  • Fax+91 2 266177458
  • Websitehttps://www.bajajhealth.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Themis Medicare Ltd3.41bn-269.80m8.37bn1.76k--2.20--2.45-2.92-2.9237.5341.290.57581.781.821,937,953.00-4.5510.17-6.3314.3863.1760.61-7.9113.521.28-1.550.2019.366.2215.00-31.463.7821.5823.36
Sigachi Industries Ltd5.06bn-550.46m8.79bn1.10k--1.73--1.74-1.46-1.4613.2013.290.63162.402.804,624,222.00-6.7012.29-9.7716.2152.8351.93-10.6214.801.275.530.24364.2322.3828.5521.6627.9148.87--
Wanbury Ltd6.58bn646.86m8.90bn1.38k13.31--11.241.3519.1319.13194.16--------4,758,967.00--8.87--101.4055.0741.829.845.62--2.97----4.1510.29-45.44-13.8844.32--
Venus Remedies Ltd7.00bn762.95m9.86bn1.30k12.92--9.871.4157.1057.10523.77--------5,391,957.00--6.67--8.0847.0237.6210.906.87--1,849.19----7.7213.8159.05--18.36--
Sakar Healthcare Ltd2.31bn252.21m9.94bn342.0039.01--20.574.3111.4511.45104.95--------6,750,901.00--4.73--5.6452.5445.5510.929.87--3.66----15.8016.4449.9612.7119.34--
IND Swift Laboratories Ltd9.64bn2.75bn11.10bn1.25k3.55--3.451.1538.2838.28122.91--------7,738,014.00--8.65--10.5951.5540.9628.5614.35---3.35--0.00-56.15-6.35-40.50--41.97--
Bajaj Healthcare Ltd6.12bn523.16m11.26bn904.0022.09--14.121.8416.1515.36188.83--------6,774,850.00--7.07--13.0746.3137.178.548.22--2.92--5.8314.615.76399.6411.21-12.65--
Jagsonpal Pharmaceuticals Ltd2.82bn409.03m11.68bn1.40k28.75--23.204.156.076.0741.76--------2,012,738.00--14.71--17.2663.6660.5914.5312.54--44.64--39.8828.7611.13146.4547.72-28.4465.72
Lincoln Pharmaceuticals Ltd6.52bn878.34m13.11bn1.85k14.92--12.862.0143.8643.86325.55--------3,518,272.00--13.22--15.4653.6450.8213.4714.56--77.35--3.327.3510.03-11.749.8720.13--
Syncom Formulations (India) Ltd5.15bn630.52m13.14bn554.0020.263.4719.232.550.690.695.564.031.248.895.419,296,547.0015.228.5617.6511.5836.5234.8112.2410.154.2473.920.0018--76.5517.7495.2828.2441.62--
Hester Biosciences Ltd3.14bn409.47m13.31bn562.0041.52--22.324.2337.6937.69277.25--------5,594,555.00--5.39--6.7273.5264.8713.5111.44--9.65--23.772.1511.1645.52-1.18-22.471.18
Beta Drugs Ltd3.86bn464.68m13.87bn399.0019.706.2722.643.6069.7265.19509.33218.940.9863.643.489,665,303.0011.8815.0816.2921.5339.7940.3012.0512.722.455.130.39740.0022.5431.8928.9637.9219.23--
Ngl Fine Chem Ltd4.47bn353.73m14.07bn456.0039.77--26.433.1557.2657.26723.35--------9,799,871.00--13.34--17.4451.6241.637.9212.15--9.06--2.858.7319.41-48.8720.4453.910.00
Data as of Feb 16 2026. Currency figures normalised to Bajaj Healthcare Ltd's reporting currency: Indian Rupee INR

Institutional shareholders

2.04%Per cent of shares held by top holders
HolderShares% Held
HDFC Asset Management Co. Ltd. (Invt Mgmt)as of 31 Jan 2026568.92k1.80%
American Century Investment Management, Inc.as of 05 Feb 202674.74k0.24%
Motilal Oswal Asset Management Co. Ltd.as of 31 Dec 2025377.000.00%
Bandhan AMC Ltd.as of 31 Jan 2026160.000.00%
More ▼
Data from 31 Dec 2025 - 31 Jan 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.